A PHASE 3, RANDOMIZED, DOUBLE-BLIND, MULTICENTER STUDY TO EVALUATE THE SAFETY AND EFFICACY OF INTRAVENOUS ICLAPRIM VERSUS VANCOMYCIN IN THE TREATMENT OF ACUTE BACTERIAL SKIN AND SKIN STRUCTURE INFECTIONS SUSPECTED OR CONFIRMED TO BE DUE TO GRAM-POSITIVE PATHOGENS. REVIVE-1

Start Date16 Jun 2016

Sponsor / Collaborator

Motif BioSciences, Inc.

EUCTR2015-002669-45-BG / Not yet recruitingPhase 3

A Phase 3, randomized, double-blind, multicenter study to evaluate the safety and efficacy of intravenous iclaprim versus vancomycin in the treatment of acute bacterial skin and skin structure infections suspected or confirmed to be due to Gram-positive pathogens. REVIVE-1 - REVIVE-1

Start Date09 May 2016

Sponsor / Collaborator

Motif BioSciences, Inc.

EUCTR2015-002687-16-HR / Not yet recruitingPhase 3

Start Date24 Mar 2016

Sponsor / Collaborator

Motif Bio Plc

100 Clinical Results associated with Iclaprim

100 Translational Medicine associated with Iclaprim

100 Patents (Medical) associated with Iclaprim

Literatures (Medical) associated with Iclaprim

01 Dec 2024·Applied Microbiology and Biotechnology

Anti-virulence potential of iclaprim, a novel folic acid synthesis inhibitor, against Staphylococcus aureus

Article

Author: Zhou, Jingwen ; Song, Haoyue ; Shu, Wen ; Hao, Lingyun ; Liu, Qingzhong ; Yang, Han ; He, Chunyan

AbstractInfections caused by Staphylococcus aureus pose a significant global public problem. Therefore, new antibiotics and therapeutic strategies are needed to combat this pathogen. This investigation delves into the effects of iclaprim, a newly discovered inhibitor of folic acid synthesis, on S. aureus virulence. The phenotypic and genotypic effects of iclaprim were thoroughly examined in relation to virulence factors, biofilm formation, and dispersal, as well as partial virulence-encoding genes associated with exoproteins, adherence, and regulation in S. aureus MW2, N315, and ATCC 25923. Then, the in vivo effectiveness of iclaprim on S. aureus pathogenicity was explored by a Galleria mellonella larvae infection model. The use of iclaprim at sub-inhibitory concentrations (sub-MICs) resulted in a reduction of α-hemolysin (Hla) production and a differential effect on the activity of coagulase in S. aureus strains. The results of biofilm formation and eradication assay showed that iclaprim was highly effective in depolymerizing the mature biofilm of S. aureus strains at concentrations of 1 MIC or greater, however, inhibited the biofilm-forming ability of only strains N315 and ATCC 25923 at sub-MICs. Interestingly, treatment of strains with sub-MICs of iclaprim resulted in significant stimulation or suppression of most virulence-encoding genes expression. Iclaprim did not affect the production of δ-hemolysin or staphylococcal protein A (SpA), nor did it impact the total activity of proteases, nucleases, and lipases. In vivo testing showed that sub-MICs of iclaprim significantly improves infected larvae survival. The present study offered valuable insights towards a better understating of the influence of iclaprim on different strains of S. aureus. The findings suggest that iclaprim may have potential as an anti-virulence and antibiofilm agent, thus potentially mitigating the pathogenicity of S. aureus and improving clinical outcomes associated with infections caused by this pathogen.Key points• Iclaprim effectively inhibits α-hemolysin production and biofilm formation in a strain-dependent manner and was an excellent depolymerizing agent of mature biofilm• Iclaprim affected the mRNA expression of virulence-encoding genes associated with exoproteins, adherence, and regulation• In vivo study in G. mellonella larvae challenged with S. aureus exhibited that iclaprim improves larvae survival

03 May 2023·The Journal of antimicrobial chemotherapy

Resistance to antibacterial antifolates in multidrug-resistant Staphylococcus aureus: prevalence estimates and genetic basis.

Article

Author: Kime, Louise ; O'Neill, Alex J ; Waring, Tina ; Mann, Benjamin F ; Mohamad, Merianne

OBJECTIVESAntibacterial antifolate drugs might have a wider role in the management of staphylococcal infection. One factor that could potentially limit their use in this context is pre-existing resistance. Here we explored the prevalence and genetic basis for resistance to these drugs in a large collection (n = 1470) of multidrug-resistant (MDR) Staphylococcus aureus.METHODSStrains were subjected to susceptibility testing to detect resistance to trimethoprim, sulfamethoxazole, co-trimoxazole and the investigational drug, iclaprim. Whole-genome sequences were interrogated to establish the genetic basis for resistance.RESULTSAccording to CLSI breakpoints, 15.2% of the strains were resistant to trimethoprim, 5.2% to sulfamethoxazole and 4.1% to co-trimoxazole. Using the proposed breakpoint for iclaprim, 89% of the trimethoprim-resistant strains exhibited non-susceptibility to this agent. Sulfamethozaxole resistance was exclusively the result of mutation in the drug target (dihydropteroate synthase). Resistance to trimethoprim and iclaprim also resulted from mutation in the target (dihydrofolate reductase; DHFR) but was more commonly associated with horizontal acquisition of genes encoding drug-insensitive DHFR proteins. Among the latter, we identified a novel gene (dfrL) encoding a DHFR with ∼35% identity to native and known resistant DHFRs, which was confirmed via molecular cloning to mediate high-level resistance.CONCLUSIONSThis study provides a detailed picture of the genotypes underlying staphylococcal resistance to antifolate drugs in clinical use and in development. Prevalence estimates suggest that resistance to the diaminopyrimidines (trimethoprim/iclaprim) is not uncommon among MDR S. aureus, and considerably higher than observed for sulfamethoxazole or co-trimoxazole.

01 Jan 2023·Acta Crystallographica Section E Crystallographic Communications

Iclaprim mesylate displaying a hydrogen-bonded molecular tape

Article

Author: Nerdinger, Sven ; Stefinovic, Marijan ; Schottenberger, Herwig ; Neuner, Sandro ; Wurst, Klaus ; Spreitz, Josef ; Griesser, Ulrich J ; Gelbrich, Thomas

The title compound, 2,6-diamino-5-[(2-cyclopropyl-7,8-dimethoxy-2H-1-benzopyran-5-yl)methyl]pyrimidin-1-ium methanesulfonate, C19H23N4O3+·CH3O3S−, is a salt made up from a protonated iclaprim molecule and a mesylate anion. The pyrimidine and chromene units of the iclaprim molecule form an orthogonal arrangement [interplanar angle of 89.67 (6)°], and the 3-nitrogen position of the pyrimidine ring is protonated. Four distinct N—H...O interactions and an additional N—H...N hydrogen bond connect iclaprim and mesylate molecules to one another, resulting in an infinite hydrogen-bonded molecular tape structure. The central section of the tape is formed by a sequence of fused hydrogen-bonded rings involving four distinct ring types.

News (Medical) associated with Iclaprim

25 Jan 2023

·www.biospace.com

Methicillin-Resistant Staphylococcus aureus Infection Pipeline Clinical Trials Featuring 25+ companies

New York, USA, Jan. 25, 2023 (GLOBE NEWSWIRE) -- Methicillin-Resistant Staphylococcus aureus Infection Pipeline Clinical Trials Featuring 25+ companies| DelveInsight Methicillin-resistant Staphylococcus aureus (MRSA) is an infection caused by antibiotic-resistant strains of the pathogen Staphylococcus aureus. Rising incidence of Methicillin-resistant Staphylococcus aureus (MRSA) infections is creating health concerns among the population. Manufacturers are focusing on product development and launches for the treatment of Methicillin-resistant Staphylococcus aureus (MRSA). DelveInsight’s 'Methicillin-Resistant Staphylococcus aureus Infection Pipeline Insight 2023' report provides comprehensive global coverage of available, marketed, and pipeline methicillin-resistant Staphylococcusaureus infection therapies in various stages of clinical development. Major pharmaceutical companies are working to advance the pipeline space and future growth potential of the methicillin-resistant Staphylococcusaureus infection pipeline domain. Key Takeaways from the Methicillin-Resistant Staphylococcus aureus Infection Pipeline Report DelveInsight’s methicillin-resistant Staphylococcusaureus infection pipeline report depicts a robust space with 25+ companies and 28+ pipeline drugs for methicillin-resistant Staphylococcusaureus infection treatment. Key methicillin-resistant Staphylococcusaureus infection companies include Trellis Bioscience, LegoChem Biosciences, Aptorum Group, ContraFect, Crystalgenomics, Cellics Therapeutics, MicuRx, Oxford Antibiotic Group, Destiny Pharma, TSRL, Inc., TAXIS Pharmaceuticals, Basilea Pharmaceutica, Helperby Therapeutics, Akagera Medicines, Histogen, Alphamab Co. Ltd, Biocidium Pharmaceuticals, and others are evaluating novel methicillin-resistant Staphylococcusaureus infection drugs candidate to improve the treatment landscape. Promising methicillin-resistant Staphylococcusaureus infection pipeline therapies in various stages of development include TRL1068, Delpazolid, ALS 4, Teicoplanin inhalation, CG 400549, SAAP 148, Exebacase, Marinus, CTI 005, Iclaprim, MRX 4, MRX 7, XF-73, TXA709, ARV-1801, ACX-375C, ABX-605, IBT-V02, BCM-0184, Contezolid, TetramOX, Ceftobiprole, HY-004B8b, HY-005B8a, CG-549, Emricasan, KN043, and several others. Ceftobiprole medocaril, the prodrug of the active moiety ceftobiprole, is a cephalosporin antibiotic for intravenous administration, with rapid bactericidal activity against a wide range of Gram-positive and Gram-negative bacteria. This includes methicillin-susceptible and resistant Staphylococcus aureus (MSSA, MRSA) and susceptible Pseudomonas spp. In October 2022, Basilea Pharmaceutica announced the results from Phase III ERADICATE study, evaluating ceftobiprole in the treatment of adult patients with bacterial bloodstream infections caused by Staphylococcus aureus. Results for the primary efficacy outcomes were consistent in key subgroups including in patients with MSSA or MRSA bloodstream infections at baseline, and in various categories of underlying conditions such as skin and skin structure infections, abdominal abscesses, chronic dialysis, septic arthritis, osteomyelitis, definite right-sided infective endocarditis and in patients with persistent SAB. Basilea also planned to submit a New Drug Application (NDA) for ceftobiprole to the US Food and Drug Administration (FDA) around year-end 2022. Exebacase (CF-301) being developed by ContraFect Corporation is a lysin with potent activity against Staphylococcus aureus ("Staph aureus"). Exebacase has the potential to be the first-in-class of a new treatment for patients with Staph aureus bacteremia. The FDA has granted Breakthrough Therapy designation to exebacase for the treatment of MRSA bloodstream infections (bacteremia), including right-sided endocarditis, when used in addition to SOC antistaphylococcal antibiotics in adult patients, based on the final data from the Phase II superiority trial of exebacase. In July 2022, Destiny Pharma plc announced that it had received an award from the Cystic Fibrosis Foundation. The research project will establish the potential of the Company’s proprietary XF-73 drug as a novel treatment for cystic fibrosis patients infected with methicillin-resistant Staphylococcus aureus (MRSA). CTI-005 is for the treatment of Methicillin Resistance Staphylococcus Aureus (MRSA) Pneumonia and has been granted IND allowance from the US FDA. The potent RBC-NS has the membrane lipids and receptors that a normal red blood cell has, however, the high surface-volume ratio of the RBC-NS allows it to act as a decoy. This characteristic allows the RBC-NS to bind and neutralize toxins, auto-antibodies, and bacterial infections. The pore-forming toxins emitted by MRSA can be effectively absorbed and neutralized by RBC-NS. Request a sample and discover the recent advances in methicillin-resistant Staphylococcusaureus infection treatment drugs @ Methicillin-Resistant Staphylococcus aureus Infection Pipeline Report The methicillin-resistant Staphylococcusaureus infection pipeline report provides detailed profiles of pipeline assets, a comparative analysis of clinical and non-clinical stage methicillin-resistant Staphylococcusaureus infection products, inactive and dormant assets, a comprehensive assessment of driving and restraining factors, and an assessment of opportunities and risks in the methicillin-resistant Staphylococcusaureus infection pipeline landscape. Methicillin-Resistant Staphylococcus aureus Infection Overview Methicillin-resistant Staphylococcus aureus (MRSA) infections are caused by bacteria that have attained resistance from several antibiotics that treat diseases caused by Staphylococcus bacteria. The common patients of Methicillin-resistant Staphylococcus aureus (MRSA) infections are patients that have been in hospitals or healthcare settings for a long duration where the bacteria is found commonly. MRSA infections are known as healthcare-associated MRSA (HA-MRSA) if infected in hospitals. Such infections can spread to healthcare workers through invasive procedures, which are further transmitted to several patients by touching and operating with bare hands. Other MRSA infections occur in a considerable population of healthy people. People associated with community-associated MRSA (CA-MRSA) show symptoms appearing as painful skin boils. It further spreads through physical contact between individuals. The population at higher risk includes people surrounded by a significant number of people and childcare workers. MRSA infections might look like red bumps, pimples, or spider bites, accompanied by pus and fever. Find out more about methicillin-resistant Staphylococcusaureus infection treatment drugs @ Drugs for Methicillin-Resistant Staphylococcus aureus Infection Treatment A snapshot of the Methicillin-Resistant Staphylococcus aureus Infection pipeline drugs mentioned in the report: Drug Company Phase MoA RoA Ceftobiprole Basilea Pharmaceutica Phase III Cell wall inhibitors; Peptidyltransferase inhibitors Intravenous CG 549 CrystalGenomics Phase II Enoyl-ACP reductase inhibitors; Fatty acid synthase expression inhibitors; Fatty acid synthetase complex inhibitors Oral BCM-0184 Biocidium Pharmaceuticals Phase I NA Oral/Topical TRL1068 Trellis Bioscience Phase I Bacterial biofilm inhibitors Intravenous ALS 4 Aptorum Group Phase I Bacterial virulence inhibitors Oral EVX-B1 Evaxion Biotech Preclinical Immunostimulants NA Emricasan Histogen Preclinical Apoptosis inhibitors; Caspase inhibitors NA TarO inhibitor Prokaryotics Discovery Cell membrane inhibitors; Cell wall inhibitors NA Learn more about the emerging methicillin-resistant Staphylococcusaureus infection pipeline therapies @ Methicillin-Resistant Staphylococcus aureus Infection Clinical Trials Methicillin-Resistant Staphylococcus aureus Infection Therapeutics Assessment The methicillin-resistant Staphylococcus aureus infection pipeline report proffers an integral view of methicillin-resistant Staphylococcusaureus infection emerging novel therapies segmented by stage, product type, molecule type, mechanism of action, and route of administration. Scope of the Methicillin-Resistant Staphylococcus aureus Infection Pipeline Report Coverage: Global Therapeutic Assessment By Product Type: Mono, Combination, Mono/Combination Therapeutic Assessment By Clinical Stages: Pre-clinical, Discovery, Discontinued, Inactive, Phase I, Phase II, Phase III Therapeutics AssessmentBy Route of Administration: Oral, Parenteral, Intravenous, Subcutaneous, Topical. Therapeutics AssessmentBy Molecule Type: Monoclonal Antibody, Peptides, Polymer, Small molecule, Gene therapy Therapeutics AssessmentBy Mechanism of Action: Cell wall inhibitors; Peptidyltransferase inhibitors, Enoyl-ACP reductase inhibitors; Fatty acid synthase expression inhibitors; Fatty acid synthetase complex inhibitors, Bacterial biofilm inhibitors, Bacterial virulence inhibitors, Immunostimulants, Apoptosis inhibitors; Caspase inhibitors, Cell membrane inhibitors; Cell wall inhibitors Key Methicillin-Resistant Staphylococcus aureus Infection Companies: Trellis Bioscience, LegoChem Biosciences, Aptorum Group, ContraFect, Crystalgenomics, Cellics Therapeutics, MicuRx, Oxford Antibiotic Group, Destiny Pharma, TSRL, Inc., TAXIS Pharmaceuticals, Basilea Pharmaceutica, Helperby Therapeutics, Akagera Medicines, Histogen, Alphamab Co. Ltd, Biocidium Pharmaceuticals, and others. Key Methicillin-Resistant Staphylococcus aureus Infection Pipeline Therapies: TRL1068, Delpazolid, ALS 4, Teicoplanin inhalation, CG 400549, SAAP 148, Exebacase, Marinus, CTI 005, Iclaprim, MRX 4, MRX 7, XF-73, TXA709, ARV-1801, ACX-375C, ABX-605, IBT-V02, BCM-0184, Contezolid, TetramOX, Ceftobiprole, HY-004B8b, HY-005B8a, CG-549, Emricasan, KN043, and others. Dive deep into rich insights for new drugs for methicillin-resistant Staphylococcusaureus infection treatment; visit @ Methicillin-Resistant Staphylococcus aureus Infection Drugs Table of Contents 1. Methicillin-Resistant Staphylococcus aureus Infection Pipeline Report Introduction 2. Methicillin-Resistant Staphylococcus aureus Infection Pipeline Report Executive Summary 3. Methicillin-Resistant Staphylococcus aureus Infection Pipeline: Overview 4. Analytical Perspective In-depth Commercial Assessment 5. Methicillin-Resistant Staphylococcus aureus Infection Pipeline Therapeutics 6. Methicillin-Resistant Staphylococcus aureus Infection Pipeline: Late Stage Products (Pre-registration) 7. Methicillin-Resistant Staphylococcus aureus Infection Pipeline: Late Stage Products (Phase III) 7.1 Ceftobiprole: Basilea Pharmaceutica 8. Methicillin-Resistant Staphylococcus aureus Infection Pipeline: Mid Stage Products (Phase II) 8.1 CG549: CrystalGenomics 9. Methicillin-Resistant Staphylococcus aureus Infection Pipeline: Early Stage Products (Phase I) 9.1 TRL1068: Trellis Bioscience 10. Methicillin-Resistant Staphylococcus aureus Infection Pipeline Therapeutics Assessment 11. Inactive Products in the Methicillin-Resistant Staphylococcus aureus Infection Pipeline 12. Company-University Collaborations (Licensing/Partnering) Analysis 13. Key Companies 14. Key Products in the Methicillin-Resistant Staphylococcus aureus Infection Pipeline 15. Unmet Needs 16. Market Drivers and Barriers 17. Future Perspectives and Conclusion 18. Analyst Views 19. Appendix For further information on the methicillin-resistant Staphylococcusaureus infection pipeline therapeutics, reach out @ Methicillin-Resistant Staphylococcus aureus Infection Treatment Drugs Related Reports Methicillin-Resistant Staphylococcus aureus Epidemiology Forecast Methicillin-Resistant Staphylococcus aureus Epidemiology Forecast – 2032 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, and the methicillin-resistant Staphylococcusaureus epidemiology trends. Methicillin-Resistant Staphylococcus aureus Infection Market Methicillin-Resistant Staphylococcus aureus Market Insights, Epidemiology, and Market Forecast – 2032 report delivers an in-depth understanding of the market trends, market drivers, market barriers, and key methicillin-resistant Staphylococcusaureus infection companies, including Trellis Bioscience, LegoChem Biosciences, Aptorum Group, Allergan, iNtRON Biotechnology, Neupharma, ImmuPharma, Lytix Biopharma, CrystalGenomics, AIMM Therapeutics, among others. Staphylococcus aureus Bacteremia Pipeline Staphylococcus aureus Bacteremia Pipeline Insight – 2023 report provides comprehensive insights about the pipeline landscape, pipeline drug pro including clinical and non-clinical stage products, and the key Staphylococcus aureus Bacteremia companies, including ContraFect, Armata Pharmaceuticals, iNtRON Biotechnology, Durata Therapeutics, Cipher Pharmaceuticals, XBiotech, Basilea Pharmaceutica, Genentech, among others. Hospital Acquired Methicillin-Resistant Staphylococcus aureus Infections Pipeline Hospital Acquired Methicillin-Resistant Staphylococcus aureus Infections Pipeline Insight – 2023 report provides comprehensive insights about the pipeline landscape, pipeline drug pro including clinical and non-clinical stage products, and the key Hospital Acquired Methicillin-Resistant Staphylococcus aureus Infections companies, including Trellis Bioscience, LegoChem Biosciences, Aptorum Group, Allergan, iNtRON Biotechnology, Neupharma, ImmuPharma, Lytix Biopharma, CrystalGenomics, AIMM Therapeutics, among others. Other Trending Reports Treatment Resistant Depression Market | Advanced Renal Cell Carcinoma Market | Brain Cancer Market | Centronuclear Myopathy Market | Head And Neck Squamous Cell Carcinoma Market | Acquired Immunodeficiency Syndrome Market | Acute Intermittent Porphyria Market | Neurovascular Devices Market | Defibrillators Market | Ventricular Hypertrophy Market | Urolithiasis Market | Alopecia Areata Market | Autonomic Dysfunction Market | Acute Ischemic Stroke Ais Market | Adenoid Cystic Carcinoma Market | Aspergillosis Market | Biliary Atresia Market | Biliary Tumor Market | Chronic Inducible Urticaria Market | Chronic Insomnia Market | Critical Limb Ischemia Market | Endometriosis Pain Market | Generalized Anxiety Disorder Gad Market | Hallux Valgus Market | Hemophilia B Market | Immunologic Deficiency Syndrome Market | Neuroblastoma Market | Neuromodulation Devices Market | Neurovascular Thrombectomy Devices Market | Osteosarcoma Market | Pemphigus Vulgaris Market | Progressive Familial Intrahepatic Cholestasis Market | Pruritus Market | Radiation Toxicity Market | Pulmonary Hypertension Associated With Interstitial Lung Disease Market | Cluster Headaches Market | Foot And Ankle Devices Market | Intravenous Immunoglobulin Market | Bile Duct Neoplasm Market | Blood Glucose Monitoring Systems Market | Rett Syndrome Market | Tissue Heart Valves Market | Cardiac Biomarkers Testing Devices Market | Subscription Healthcare | Hepatorenal Syndrome Market | Central Venous Catheters Market | Continuous Renal Replacement Therapy Machines Market | Nonalcoholic Steatohepatitis Market | Necrotizing Enterocolitis Market | Cardiac Amyloidosis Market | Artificial Iris Market | Aortic Aneurysm Stent Grafts Market | Polypoidal Choroidal Vasculopathy Market | Adrenal Crisis Market | Hearing Implants Market | Image Guided Surgery Devices Market | Angioedema Market | Bladder Cancer Market Related Healthcare Services Healthcare Consulting Healthcare Competitive Intelligence Services Healthcare Asset Prioritization Services About DelveInsight DelveInsight is a leading Business Consultant, and Market Research firm focused exclusively on life sciences. Connect with us atLinkedIn Contact Us Shruti Thakur info@delveinsight.com +1(919)321-6187

Phase 3Phase 2Clinical Result

16 Jun 2022

·www.prnewswire.com

Worldwide Anti-aging Therapeutics Industry to 2040 - Rising Aging Population is Driving Growth

DUBLIN, June 16, 2022 /PRNewswire/ -- The "Anti-aging Therapeutics Market - Distribution by Type of Molecule, Type of Aging and Key Geographies - Industry Trends and Global Forecasts, 2022-2040" report has been added to ResearchAndMarkets.com's offering. This report features an extensive study of the current market landscape and future potential of anti-aging therapeutics over the next decade. The study features an in-depth analysis of the key drivers and trends related to this domain. The advancements in health care and available technologies have inadvertently led to an increase in the life expectancy of individuals. However, this has also led to a rise in the aging population worldwide. According to the United Nations, the aforementioned trend is one of the key transformations observed in the 21st century; it is expected to have an impact on all sections of the society. Aging is linked to a variety of diseases, including cardiovascular disorders, neurodegenerative disorders, oncological disorders and musculoskeletal disorders, which further puts heavy economic and psychological burden on the patients, their families and the society. As per the World Health Organization, in 2020, close to 1 billion people were estimated to be aged 65 or above, globally. In addition, the share of elderly population is expected to increase from 9.3% in 2020 to 16% in 2050. Aging biology is still a largely unexplored field, in terms of the development of safe and effective novel pharmacotherapies. Anti-aging therapeutics, therefore, is an emerging field of medical science focused on reducing or reversing the underlying causes of aging through different mechanisms, in order to extend healthy lifespan of humans. Given the rapidly growing aging population, the ongoing efforts to discover drugs that enhance the lifespan of an individual by targeting the pathogenesis of aging have become a popular topic for research. At present, various anti-aging products and devices, including direct-to-consumer nutraceuticals, plastic surgeries, cosmetics, skincare products and devices, are available in the market to slow the process of aging. Further, several start-ups and academic / research institutes across the world are evaluating various types of anti-aging therapeutics, including stem cell therapies, metformin, rapamycin, resveratrol and senolytics (drugs that selectively clear senescent cells), in multiple preclinical / clinical studies. Owing to the encouraging results demonstrating the ability of novel drugs in delaying the aging process, capital investments worth USD 4 billion have been made by various private and public sector investors in the last five years to fund product development initiatives. Moreover, over 660 patents related to anti-aging therapeutics have been recently filed / granted, demonstrating the continued innovation in this domain. Driven by the growing aging population, ongoing pace of innovation in this field and financial support from investors, the anti-aging therapeutics market is anticipated to witness substantial growth in the mid to long-term. Amongst other elements, the report includes: A detailed assessment of the current market landscape of anti-aging therapeutics, featuring information on phase of development (commercial, phase II, phase I / II, phase I, clinical (phase unknown), discovery / preclinical and undisclosed), type of aging (cellular aging, metabolic aging, immune aging, others and undisclosed), type of molecule (biologics and small molecules), mechanism of action (senolytic, cell regeneration, mammalian target of rapamycin (mTOR) inhibitor / modulator, adenosine monophosphate (AMP)-kinase / AMP activator, mitochondria inhibitor / modulator and others) and type of developer (industry and non-industry). In addition, the chapter features analyses of anti-aging therapeutic developers based on parameters, such as year of establishment, company size, location of headquarters and leading developers (in terms of number of pipeline candidates). A competitiveness analysis of anti-aging therapeutic developers, based on various relevant parameters, namely supplier power (based on the experience of the developer) and company competitiveness (based on highest phase of development, type of aging and type of molecule). An analysis of partnerships that have been inked by stakeholders engaged in this domain, during the period 2018-2022. Further, the partnership activity in this domain has been analyzed based on various parameters, such as year of partnership, type of partnership, most active players (in terms of number of partnerships), type of partner and regional distribution of collaborations. A detailed analysis of investments that have been made into companies which are developing proprietary anti-aging therapeutics, during period 2018-2022. The various types of funding instances reported in this domain include pre-seed financing, seed financing, venture capital financing, capital raised from IPOs and subsequent public offerings, grants, crowdfunding, and donations. An in-depth analysis of the various patents that have been filed / granted related to anti-aging therapeutics, during 2018-2022, taking into consideration parameters, such as publication year, type of patent, geographical region, CPC symbols, key focus areas, type of applicant, patent age and leading players (in terms of size of intellectual property portfolio). It also features a patent benchmarking analysis and a detailed valuation analysis. A detailed review of more than 220 peer-reviewed, scientific articles related to research on anti-aging therapeutics, during the period 2018-2022, based on several relevant parameters, such as year of publication, type of publication, popular keywords and geography of affiliations. The chapter also provides information on the most popular publisher, most popular journal, most popular affiliations and most popular funding institutes (in terms of number of articles published). A qualitative analysis, highlighting the five competitive forces prevalent in this domain, including threats for new entrants, bargaining power of suppliers, bargaining power of buyers, threats of substitute products and rivalry among existing competitors. Elaborate profiles of prominent players engaged in the development of anti-aging therapeutics, featuring a brief overview of the company, details related to its product portfolio, recent developments and an informed future outlook. Key Questions Answered Who are the leading players engaged in the development of anti-aging therapeutics? What types of partnership models are commonly adopted by industry stakeholders engaged in this industry? Who are the key investors in the anti-aging therapeutics domain? How is the intellectual property landscape in this field likely to evolve in the foreseen future? What is the evolving trend of publications focused on anti-aging therapeutics? What are the key value drivers that are likely to influence the evolution of this upcoming market? How is the current and future market opportunity likely to be distributed across key market segments? Key Topics Covered: 1. PREFACE 2. EXECUTIVE SUMMARY 3. INTRODUCTION 4. MARKET LANDSCAPE 5. COMPANY COMPETITIVENESS ANALYSIS 5.1. Chapter Overview 5.2. Assumptions and Key Parameters 5.3. Methodology 5.4. Anti-aging Therapeutics: Company Competitiveness Analysis 5.4.1. Small Companies 5.4.2. Mid-sized and Large Companies 6. PARTNERSHIPS AND COLLABORATIONS 6.1. Chapter Overview 6.2. Anti-aging Therapeutics: Partnerships and Collaborations 6.2.1 Analysis by Year of Partnership 6.2.2. Analysis by Type of Partnership 6.2.3. Analysis by Year and Type of Partnership 6.2.4. Leading Players: Analysis by Number of Partnerships 6.2.5. Analysis by Type of Partner 6.2.6. Analysis by Type of Agreement 6.2.7. Analysis by Region 6.2.7.1. Intercontinental and Intracontinental Deals 6.2.7.2. International and Local Deals 7. FUNDING AND INVESTMENTS 7.1. Chapter Overview 7.2. Anti-aging Therapeutics: Funding and Investments 7.2.1. Analysis of Instances by Year 7.2.2. Analysis of Amount Invested by Year 7.2.3 Analysis of Instances by Type of Funding 7.2.4. Analysis of Amount Invested by Type of Funding 7.2.5. Analysis by Type of Investor 7.2.6. Analysis by Focus Area 7.2.7. Analysis of Amount Invested by Region 7.2.8. Analysis of Amount Invested by Country 7.2.9. Most Active Investors: Analysis by Number of Instances 7.2.10. Most Active Players: Analysis by Number of Instances 7.2.11. Most Active Players: Analysis by Amount Invested 8. PATENT ANALYSIS 8.1. Chapter Overview 8.2. Scope and Methodology 8.3. Anti-aging Therapeutics: Patent Analysis 8.3.1. Analysis by Type of Patent 8.3.2. Analysis by Patent Publication Year 8.3.3. Analysis of Granted Patents by Year 8.3.4. Analysis by Geography 8.3.5. Analysis by CPC Symbols 8.3.6. Analysis by Type of Applicant 8.3.7. Analysis by Emerging Focus Areas 8.3.8. Analysis by Patent Age 8.3.9. Leading Industry Players: Analysis by Number of Patents 8.3.10. Leading Non-Industry Players: Analysis by Number of Patents 8.3.11. Leading Individual Assignees: Analysis by Number of Patents 8.4. Anti-aging Therapeutics: Patent Benchmarking 8.4.1. Analysis by Patent Characteristics 8.5. Anti-aging Therapeutics: Patent Valuation 9. PUBLICATION ANALYSIS 9.1. Chapter Overview 9.2. Scope and Methodology 9.3. Anti-aging Therapeutics: Publication Analysis 10. PORTER'S FIVE FORCES ANALYSIS 11. COMPANY PROFILES 11.1. AgelessRx 11.1.1. Company Overview 11.1.2. Product Portfolio 11.1.3. Recent Developments and Future Outlook 11.2. ANOVA Institute for Regenerative Medicine 11.2.1. Company Overview 11.2.2. Product Portfolio 11.2.3. Recent Developments and Future Outlook 11.3. Betterhumans 11.3.1. Company Overview 11.3.2. Product Portfolio 11.3.3. Recent Developments and Future Outlook 11.4. BioAge Labs 11.4.1. Company Overview 11.4.2. Product Portfolio 11.4.3. Recent Developments and Future Outlook 11.5. bioXcellerator 11.5.1. Company Overview 11.5.2. Product Portfolio 11.5.3. Recent Developments and Future Outlook 11.6. Cambrian Biopharma 11.6.1. Company Overview 11.6.2. Product Portfolio 11.6.3. Recent Developments and Future Outlook 11.7. Gero.ai 11.7.1. Company Overview 11.7.2. Product Portfolio 11.7.3. Recent Developments and Future Outlook 11.8. Mayo Clinic 11.8.1. Company Overview 11.8.2. Product Portfolio 11.8.3. Recent Developments and Future Outlook 11.9. Rejuvenate Bio 11.9.1. Company Overview 11.9.2. Product Portfolio 11.9.3. Recent Developments and Future Outlook 11.10. UT Health San Antonio 11.10.1. Company Overview 11.10.2. Product Portfolio 11.10.3. Recent Developments and Future Outlook 12. MARKET FORECAST AND OPPORTUNITY ANALYSIS 12.1. Forecast Methodology and Key Assumptions 12.2. Global Anti-aging Therapeutics Market, 2022-2040 12.2.1. Anti-aging Therapeutics Market: Analysis by Type of Molecule 12.2.2. Anti-aging Therapeutics Market: Analysis by Type of Aging 12.2.3. Anti-aging Therapeutics Market: Analysis by Geography 12.2.3.1. Anti-aging Therapeutics Market in North America, 2022-2040 12.2.3.2. Anti-aging Therapeutics Market in Europe, 2022-2040 12.2.3.3. Anti-aging Therapeutics Market in Asia Pacific, 2022-2040 12.2.3.4. Anti-aging Therapeutics Market in Rest of the World, 2022-2040 12.2.4. Anti-aging Therapeutics: Forecast of Individual Product Sales 12.2.4.1. bioXgel (PRP) (bioXcellerator): Estimated Sales Revenues 12.2.4.2. AR-100 (Rejenevie Therapeutics): Estimated Sales Revenues 12.2.4.3. BGE-117 (BioAge Labs): Estimated Sales Revenues 12.2.4.4. Dasatinib and Quercetin (TruDiagnostic): Estimated Sales Revenues 12.2.4.5. MYMD-1 (MyMD Pharmaceuticals): Estimated Sales Revenues 12.2.4.6. TRIIM Treatment (Intervene Immune): Estimated Sales Revenues 12.2.4.7. Rapamycin (AgelessRx): Estimated Sales Revenues 12.2.4.8. Sarconeos (BIO101) (Biophytis): Estimated Sales Revenues 13. EXECUTIVE INSIGHTS 13.1. Chapter Overview 13.2. Gero.ai 13.2.1 Company Snapshot 13.2.2. Interview Transcript: Peter Fedichev (Co-founder and Chief Executive Officer) 13.3. Betterhumans 13.3.1. Company Snapshot 13.3.2. Interview Transcript: James Clement (President) 13.4. CytoMed Therapeutics 13.4.1. Company Snapshot 13.4.2. Interview Transcript: Wee Kiat Tan (Chief Operating Officer) 13.5. Cambrian Biopharma 13.5.1 Company Snapshot 13.5.2. Interview Transcript: Rosa Argyropoulos (Senior Director of Global Corporate Communications) 13.6. Landmark Medical Centre 13.6.1 Company Snapshot 13.6.2. Interview Transcript: Lucas Luk Tien Wee (Director and Consultant Obstetrician and Gynaecologist) 14. APPENDIX I: TABULATED DATA 15. APPENDIX I1: LIST OF COMAPANIES AND ORGANIZATIONS For more information about this report visit Media Contact: Research and Markets Laura Wood, Senior Manager [email protected] For E.S.T Office Hours Call +1-917-300-0470 For U.S./CAN Toll Free Call +1-800-526-8630 For GMT Office Hours Call +353-1-416-8900 U.S. Fax: 646-607-1904 Fax (outside U.S.): +353-1-481-1716 SOURCE Research and Markets

Cell TherapySmall molecular drugCollaborate

08 Jun 2022

·www.prnewswire.com

Anti-aging Therapeutics Market worth $ 2013.5 Million by 2030 - Exclusive Report by InsightAce Analytic

JERSEY CITY, N.J., June 8, 2022 /PRNewswire/ -- InsightAce Analytic Pvt. Ltd. announces the release of market assessment report on "Global Anti-aging Therapeutics Market (Type of Molecule (Biologics and Small Molecules), Type of Aging (Cellular Aging, Immune Aging, Metabolic Aging and Others), Mechanism of Action (Senolytic, Cell Regeneration, mTOR inhibitor/Modulator, AMP-kinase/AMP Activator, Mitochondria Inhibitor/Modulator and Others))– Industry Analysis, Competitive Landscape, Revenue Forecast 2020-2030" According to the latest research by InsightAce Analytic, the global Anti-aging Therapeutics market size valued at US$ 518.86 million in 2021, and it is expected to reach US$ 2013.51 million in 2030, recording a promising CAGR of 16.53% during the period of 2022-2030. Request for Sample Pages: Aging populations are increasing the prevalence of age-related illnesses, causing individual and social concerns. The demand for effective regenerative medicine solutions for the elderly is higher than ever. Anti-Aging Therapeutics has emerged as a new medical science field. Anti-aging diagnosis and medicine, which is a subset of medical and healthcare, uses modern science and medical technology to identify, prevent, cure, and reverse age-related dysfunctions, illnesses, and diseases. Several cell, insect, and animal models may be useful beginning areas in the development of anti-aging medicines prior to human trials. Interest and expenditure in anti-aging medicines are rising exponentially as living conditions improve. Several companies have also focused their efforts on stem cells and regenerative medicine. Given the numerous applications of stem cells, applications in regenerative medicine are far beyond ageing disorders and illnesses. Nonetheless, a few organizations have concentrated specifically on age-related problems. For instance, In Feb 2021, Cambrian Biopharma received $60 million in private funding for the development of anti-aging medications. The "Nine Hallmarks of Aging," which include cellular senescence, persistent tissue inflammation, and mitochondrial malfunction, are the focus of research of Cambrian scientists. Researchers are utilizing advancements in immunology, genomics, and epigenetics, as well as technologies ranging from gene editing to novel stem cell treatments. There is substantial potential for anti-aging therapeutics companies that effectively launch longevity treatments. Despite these encouraging breakthroughs in the field of ageing, a number of barriers will become obvious once an anti-aging medicine undergoes the demanding clinical trial procedure. Market growth is primarily related to a rise in demand for individualized, precise, preventative, and participative ageing therapies, as well as an increase in the Geriatric Population. As a result, as the number of the elderly rises, so does the need for anti-aging treatments. Increased technological advancements and R&D spending on anti-ageing products are propelling the market forward. To meet the growing demand for technologically advanced solutions among customers, companies in the field have mainly developed revolutionary anti-ageing therapeutics products. With a rising healthcare industry, North America is expected to have the largest revenue shares in 2022. Research and development into pharmaceuticals are rising in major economies such as the United States and Canada, and this is due to the increased investment in pharmaceutical design, production as well as research into senescent cells. Moreover, Asia Pacific is the world's most populous region, and it has a sizable market for anti-aging therapeutics. The ever-increasing proportion of elderly people in the population is a potential customer base for anti-aging treatments, driving regional growth. Enquiry Before Buy: Major key Players in the Anti-aging Therapeutics market are AgelessRx, ANOVA Institute for Regenerative Medicine, Betterhumans, BioAge Labs, BIOPHYTIS BSA, bioXcellerator, Cambrian Biopharma, CytoMed Therapeutics, Gero.ai, Rejuvenate Bio, Rejenevie Therapeutics, UT Health San Antonio, MyMD Pharmaceuticals, Intervene Immune, Inc. , CohBar, Inc., Alkahest, Athersys Inc, BHB Therapeutics, Biosplice, Cyclo Therapeutics, Denali Therapeutics, Elysium Health, Genome Protection, GenSight Biologics, Intervene Immune, Khondrian, Longeveron, LyGenesis, Mesoblast, Minovia Therapeutics, Mitobridge, Navitor Pharmaceuticals, NeuroTrack, Nuchido, NuSirt, OneSkin Technologies, PharmatrophiX, Proteostasis Therapeutics, Retrotope, Stealth Biotherapeutics, TA Sciences, Unity Biotechnology Younger Phenotype, and Other Prominent Players Recent Key Developments: In Feb 2022, Cambrian Biopharma announced that it had entered into a licence arrangement with Novartis to promote innovative, selective drugs that target the mechanistic target of rapamycin (mTOR) pathway. These compounds were conceived and characterized by Novartis. Cambrian Biopharma informed via a statement that the licensed assets are structural analogues of the FDA-approved drug rapamycin. This drug has been shown to prevent or reverse multiple age-related health deficits in mice and to extend their average lifespan by up to 31 %, according to the information provided by Cambrian Biopharma. In May 2019, Rejenevie™ Therapeutics announced the initiation of the Company's Phase II clinical trial to explore the safety and effectiveness of its unique AR-100 immune restoration treatment to increase the function of the ageing immune system. The clinical-stage biotechnology company develops first-in-world stem cell restoration medicines targeting age-related disorders. In April 2022, MyMD Pharmaceuticals Inc. accelerated the dosing of additional patients in the Company's fully funded Phase 2 clinical study of lead drug candidate MYMD-1 as a treatment for delaying ageing and extending a healthy lifespan. The double-blind, placebo-controlled, randomized Phase 2 research (NCT05283486) explores the effectiveness, safety, and pharmacokinetics of MYMD-1® in the treatment of people aged 65 years or older with chronic inflammation associated with sarcopenia/frailty. Market Segments Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2020 to 2030 based on Type of Molecule Biologics Small Molecules Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2020 to 2030 based on Type of Aging Cellular Aging Immune Aging Metabolic Aging Others Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2020 to 2030 based on Mechanism of Action Senolytic Cell Regeneration mTOR inhibitor/Modulator AMP-kinase/AMP Activator Mitochondria Inhibitor/Modulator Others Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2020 to 2030 based on Region North America Europe Asia Pacific Latin America Middle East & Africa North America Anti-aging Therapeutics market revenue (US$ Million) by Country, 2020 to 2030 U.S. Canada Europe Anti-aging Therapeutics market revenue (US$ Million) by Country, 2020 to 2030 Germany France Italy Spain Russia Rest of Europe Asia Pacific Anti-aging Therapeutics market revenue (US$ Million) by Country, 2020 to 2030 India China Japan South Korea Australia & New Zealand Latin America Anti-aging Therapeutics market revenue (US$ Million) by Country, 2020 to 2030 Brazil Mexico Rest of Latin America Middle East & Africa Anti-aging Therapeutics market revenue (US$ Million) by Country, 2020 to 2030 GCC Countries South Africa Rest of Middle East & Africa Why should buy this report: To receive a comprehensive analysis of the prospects for global Anti-aging Therapeutics market To receive industry overview and future trends of global Anti-aging Therapeutics market To analyse the Anti-aging Therapeutics market drivers and challenges To get information on Anti-aging Therapeutics market size value (US$ Mn) forecast till 2030 Major Investments, Mergers & Acquisition in global Anti-aging Therapeutics market industry For Customization @ Other Related Reports Published by InsightAce Analytic: Global Longevity and Anti-Senescence Therapy Market Global Antisense Oligonucleotide Therapeutics Market Global Anti-Ageing Products Services and Devices Market About Us: InsightAce Analytic is a market research and consulting firm that enables clients to make strategic decisions. Our qualitative and quantitative market intelligence solutions inform the need for market and competitive intelligence to expand businesses. We help clients gain competitive advantage by identifying untapped markets, exploring new and competing technologies, segmenting potential markets and repositioning products. Our expertise is in providing syndicated and custom market intelligence reports with an in-depth analysis with key market insights in a timely and cost-effective manner. Contact Us: InsightAce Analytic Pvt. Ltd. Tel.: +1 718 593 4405 Email: [email protected] Site Visit: Follow Us on LinkedIn @ bit.ly/2tBXsgS Follow Us On Facebook @ bit.ly/2H9jnDZ SOURCE InsightAce Analytic Pvt. Ltd.

OligonucleotideSmall molecular drugAcquisition

100 Deals associated with Iclaprim

External Link

KEGG	Wiki	ATC	Drug Bank
D08337	Iclaprim	J01EA03	DB06358

R&D Status

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Skin and skin structure infections	Phase 3	PL	Motif Bio Plc	01 Nov 2015
Skin and skin structure infections	Phase 3	UA	Motif Bio Plc	01 Nov 2015
Skin and skin structure infections	Phase 3	US	Motif Bio Plc	01 Nov 2015
Skin and skin structure infections	Phase 3	PR	Motif Bio Plc	01 Nov 2015
Skin and skin structure infections	Phase 3	PE	Motif Bio Plc	01 Nov 2015
Skin and skin structure infections	Phase 3	CO	Motif Bio Plc	01 Nov 2015
Skin and skin structure infections	Phase 3	DE	Motif Bio Plc	01 Nov 2015
Skin and skin structure infections	Phase 3	CL	Motif Bio Plc	01 Nov 2015
Skin Diseases, Bacterial	Phase 3	US	Arpida AG	01 Mar 2006
Complicated skin and skin structure infection	Phase 3	US	Arpida AG	01 Jun 2005

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT02600611 \| NCT02607618 (REVIVE-1 and REVIVE-2, Pubmed \| J Microbiol Immunol Infect)	Phase 3	Skin and skin structure infections	-	Iclaprim 80 mg	(gehxxyjlcz) = bmqtazshrg ymoxefznrq (effcrmggrz )	Positive	01 Aug 2018
				Vancomycin 15 mg/kg	(gehxxyjlcz) = hyaucwzquf ymoxefznrq (effcrmggrz )
NCT02607618 (REVIVE-2, CTgov)	Phase 3	Skin structures and soft tissue infections	613	Iclaprim (Iclaprim)	iqvzrmlizw(lkkzmeswlf) = obwcehihvv skcmlknfgt (txzdttnuef, zmbsslvbxe - bsqqvnbfxi) View more	-	11 Jul 2018
				Vancomycin (Vancomycin)	iqvzrmlizw(lkkzmeswlf) = iterpxrqqw skcmlknfgt (txzdttnuef, hzswhbhqsn - hrgslurlhy) View more
NCT02600611 (REVIVE-1, CTgov)	Phase 3	Skin structures and soft tissue infections \| Skin and skin structure infections	600	iclaprim (Iclaprim)	bjfxceexww(ybwipulduv) = zdamqscnlh bwbuvcrlzn (avpolxykvq, bpojrutdfv - ikecajgihq) View more	-	19 Jun 2018
				Vancomycin (Vancomycin)	bjfxceexww(ybwipulduv) = lxzzyeevev bwbuvcrlzn (avpolxykvq, gcgvazhctk - ltlcpsgqhd) View more
NCT02607618 (REVIVE-2, Pubmed \| Antimicrob Agents Chemother) Manual	Phase 3	Skin and skin structure infections	613	Intravenous Iclaprim	oppmolvezt(bvbpbbyesl) = svehnppqed ctbxzxaqyu (bokqdfhhpm )	Non-superior	26 Apr 2018
				Vancomycin	oppmolvezt(bvbpbbyesl) = yuyftdwusg ctbxzxaqyu (bokqdfhhpm )
NCT02600611 (REVIVE-1, Pubmed \| Clin Infect Dis)	Phase 3	Skin and skin structure infections	600	Iclaprim 80 mg	(bmemqrjqoc) = dkuqilgmqw fjzgmfdvqa (odbghbptul )	Positive	03 Apr 2018
				Vancomycin 15 mg/kg	(bmemqrjqoc) = fcyzcodgbc fjzgmfdvqa (odbghbptul )

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis